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Results The median progression-free survival (PFS) 
was significantly shorter in carriers of TT genotype of the 
STMN1 gene compared with patients with CC or CT gen-
otypes (2.75 vs. 6.5 months; p = 0.0033; HR 5.91, 95 % 
CI 1.81–19.33). Evaluated SNP did not significantly affect 
the response to treatment and the overall survival of the 
patients.
Conclusion Rare TT genotype of STMN1 gene may be 
an unfavorable predictive factor of chemotherapy based 
on platinum compounds and vinorelbine, in patients with 
NSCLC.
Keywords Non-small cell lung cancer · Polymorphism · 
STMN1 · Chemotherapy
Introduction
Lung cancer still remains the most common malignant 
neoplasm in developed countries. In 2012, 1.8 million 
new cases and 1.59 million deaths due to lung cancer were 
recorded. Most prevalent histological subtype (85 % of 
cases) of this cancer is non-small cell lung cancer (NSCLC) 
[1]. The majority of patients with NSCLC are diagnosed at 
an advanced stages of the disease (inoperable cases IIIA, 
IIIB, IV), which also disqualifies them from radical sur-
gery. These patients can only be subjected to chemotherapy 
(CTH) or radiochemotherapy (RCTH) of moderate efficacy.
Currently, standard first-line treatment of patients 
with locally advanced and metastatic NSCLC based 
on a combination of platinum compounds with third-
generation drug (gemcitabine, vinorelbine, docetaxel, 
and pemetrexed). Unfortunately, objective response rate 
(ORR) obtained on the basis of this kind of treatment 
usually does not exceed 30–40 %. Use of first-line CTH 
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extends median overall survival (OS) by approximately 
1.5 months and increases the probability of one-year 
survival by approximately 9 % compared with patients 
treated with best supportive care [2].
At present the highest efficiency of treatment of 
locally advanced and metastatic NSCLC can be achieved 
in appropriately selected (mainly based on genetic pre-
disposition) groups of patients in whom molecularly 
targeted drugs are used, e.g., erlotinib, gefitinib, and 
crizotynib [3, 4]. However, these drugs are reserved 
only for group of patients who have certain molecu-
lar abnormalities (depending on the race 9–51 % of 
patients with NSCLC have EGFR activating mutations; 
3–7 % have ALK rearrangements) [5–7]. Therefore, still 
an overwhelming number of patients receive standard 
CTH. Recent research indicate that even in this group 
of patients, genetic predispositions can be used to select 
potentially the most effective treatment regimen, which 
will not only prolong the life of patients, but also improve 
the quality of life [8, 9].
Vinorelbine (5′-noranhydro vinblastine, VNR) is a 
semisynthetic derivative of vinblastine with antitumor 
activity. Like other vinca alkaloids (Lat. Vinca rosea, 
Catharanthus roseus), i.e., vinblastine and vincristine, 
this cytostatic has been applied, in the treatment of dif-
ferent cancers. Vinorelbine, like the other vinca alka-
loids and taxanes, exerts its action by binding to tubulin. 
As a result of tubulin polymerization blocking (reverse 
mechanism than in the case of taxanes), depolymeriza-
tion occurs followed inhibition of cells division at mito-
sis (phase-specific drug acting on the M phase of the cell 
cycle), which in turn leads to apoptosis of the cell [10]. 
As in the case of taxanes, in the mechanism of resistance 
to vinorelbine, certain disorders in functioning of the 
stathmin-1 protein may be critical (oncoprotein-18 and, 
stathmin-1 STMN1).
STMN1 is a protein whose expression is regulated by 
the product of p53 suppressor gene. Experimental studies 
have shown that STMN1 significantly affects the dynam-
ics of microtubules [11, 12]. To date, in available litera-
ture, there is only one publication that contains data on 
influence of any of the polymorphisms in the STMN1 gene 
(including −2166T>C, rs182455) on the effectiveness of 
any of the currently used CTH regimens in lung cancer 
[13]. However, on the basis of information about the cor-
relation between the expression of STMN1 and efficacy 
of therapies based on the taxane or vinca alkaloids and 
that −2166T>C single nucleotide polymorphism (SNP) 
is located within or close to the putative transcriptional 
control region [14], it can be concluded that there exists 
potential predictive importance of this kind of genetic 
change (polymorphisms) in lung cancer patients.
The aim of this study was to determine the association 
between a SNP of STMN1 gene promoter (−2166T>C) 
and the effectiveness of chemotherapy based on platinum 
compounds and vinorelbine in patients with unresectable, 
locally advanced or metastatic NSCLC.
Materials and methods
Study group
The study included 110 Caucasians patients with inoper-
able, locally advanced, and advanced NSCLC (IIIB and IV), 
treated in 2010–2013 at the Department of Pneumonology, 
Oncology and Allergology, Medical University of Lublin. In 
order to participate in the study, written informed consent for 
use of clinical data and peripheral blood were obtained from 
each patient. The study design was approved by the Com-
mittee of Ethics and Research at the Medical University of 
Lublin (consent no.: KE-0254/142/2010). NSCLC diagno-
ses were made on the basis of the result of histological or 
cytological examination of material obtained from primary 
tumor or metastases. Characteristics of the study group are 
presented in Table 1. All patients received the first line of 
CTH-standard doublet scheme based on platinum compound 
and vinorelbine. Disease severity at the start of treatment 
was assessed according to the TNM classification (VII edi-
tion by UICC). The median number of first-line CTH cycles 
was 4. In the study group, 30 % of patients were subjected 
to RCTH. Subsequent lines of therapy (using drugs such as 
erlotinib, docetaxel, or pemetrexed) were used for 28.2 % 
of patients. On the basis of the interview and the available 
medical records, detailed demographic and clinical data 
(gender, age, smoking status, histological type of tumor, 
stage of disease, weight loss, performance status (PS), pres-
ence of hematological disorders, the incidence of cancer in 
the family), and on the course of treatment (type and number 
of CTH or RCTH cycles, side effects and the effectiveness of 
therapy) were collected. Response to treatment was assessed 
by response evaluation criteria in solid tumors (RECIST, ver-
sion 1.1). The occurrence of adverse events was assessed on 
the basis of the common toxicity criteria (CTC) guidelines 
(version no. 4.03). We also evaluated the differences in the 
length of progression-free survival (PFS) and OS in patients 
treated with first-line CTH depending on the clinical features 
and analyzed genetic polymorphism.
DNA extraction and genotyping
For the isolation of DNA from peripheral blood leuko-
cytes, a set of QIAamp DNA Blood Mini Kit (Qiagen, 
Canada) was used. Evaluation of the isolated DNA was 
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made using a spectrophotometer BioPhotometer plus, 
cuvette equipped with filters UV/Vis (Eppendorf, Ger-
many). STMN1 gene SNP analysis was performed using 
a mini-sequencing technique (SNaPshot™ PCR). For the 
reaction, a set of ABI PRISM® SNaPshot™ Multiplex Kit 
(Life Technologies, USA) was used (representative results 
of genotyping obtained by SNaPshot PCR products capil-
lary electrophoresis is shown on Fig. 1).
Statistical analysis
Genotyping results of analyzed gene were retrospectively 
associated with: objective response (OR) to treatment, the 
length of PFS, and OS of the patients. The statistical analy-
sis of the results was performed using the computer soft-
ware: Statistica 10 (Statsoft, USA), MedCalc 10 (MedCalc 
Software, Belgium). Results with the values of p < 0.05 
were considered statistically significant. Using the Chi-
square (χ2) test, the balance of the Hardy–Weinberg (HW) 
was rated, relationship of a series of demographic and clin-
ical factors with the distribution of polymorphic variants of 
the STMN1 gene and the impact of this SNP on OR. The 
Kaplan–Meier method was used to compare the probabil-
ity of PFS and OS in patients with distinct clinical–demo-
graphic characteristics and the genotypes of the analyzed 
gene. Cox regression model with a stepwise selection 
with minimum AIC factor (Akaike Information Criterion) 
was used to assess which of the clinical and genetic fac-
tors affect survival. The Mann–Whitney U test was used to 
compare the median survival in the groups having various 
distributions of demographic, clinical, and genetic factors.
Results
Response to treatment
The distribution of STMN1 genotypes (−2166T>C) did not 
depend on factors such as gender, age, histological sub-
type, stage of disease, PS, or smoking status (Table 2). 
Genotypes of STMN1 gene were in Hardy–Weinberg 
equilibrium. CC, CT, and TT genotypes of STMN1 gene 
(−2166T>C) occurred, respectively, in 45.4, 47.2 and 7.4 % 
of patients.
In the whole group, there were no patients with com-
plete remission (CR) as a result of first-line CTH treatment. 
Control of the disease was observed in 59.1 % of patients, 
of which partial remission (PR) and stable disease (SD) 
occurred in 25.5 and 33.6 % of patients. Progression disease 
(PD) was observed in 40.9 % of patients. The incidence of 
PD was higher in patients with body weight loss compared 
with those with unaltered weight (p = 0.046, χ2 = 4). In the 
case of other demographic and clinical factors such as gender, 
age, smoking status, histological type of tumor, PS, stage of 
disease, the use of RCTH, or the incidents of cancer in the 
family, there were no statistically significant differences in 
Table 1  Patient characteristics
Variable Study group (n = 110)
Sex
 Male 85 (77.3 %)
 Female 25 (22.7 %)
Age (years)
 Median 61




 Mean ± std dev. 40 ± 23.1
 Non-smokers 5 (4.5 %)
 Current smokers 75 (68.2 %)
 Former Smokers 27 (24.6 %)
 No data 3 (2.7 %)
Histopathological diagnosis
 Adenocarcinoma 11 (10 %)
 Squamous cell carcinoma 78 (70.9 %)
 Large cell carcinoma 8 (7.3 %)
 NOS (not otherwise specified) 13 (11.8 %)
Stage of disease
 IIIB 56 (50.9 %)
 IV 54 (49.1 %)
Performance status
 PS = 0 30 (27.3 %)
 PS ≥ 1 15 (72.7 %)
Weight loss before CTH
 Yes 67 (60.9 %)
 No 33 (30 %)
 No data 10 (9.1 %)
Anemia before CTH
 Yes 70 (63.6 %)
 No 40 (36.4 %)
Number of cycles of first-line CTH
 Median 4
 Mean ± std dev. 3.7 ± 1.5
Side effect after first-line CTH
 Yes 60 (54.5 %)
 No 40 (36.4 %)
 No data 10 (9.1 %)
Radiotherapy
 Yes 33 (30 %)
 No 77 (70 %)
Subsequent lines of treatment
 Yes 79 (71.8 %)
 No 31 (28.2 %)
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Fig. 1  Example of genotyping results obtained by capillary electrophoresis of the SNaPshot PCR products. From left CT heterozygote, TT, and 
CC homozygote (analysis performed on the opposite strand where A=T and G=C)
Table 2  STMN1 gene genotype distribution according to demographic and clinical factors
Variable STMN1 (−2166T>C) p, χ2
Genotype CC 49 (45.4 %) Genotype CT 51 (47.2 %) Genotype TT 8 (7.4 %)
Sex
 Male 37 (44.1 %) 39 (46.4 %) 8 (9.5 %) 0.2891
 Female 12 (50 %) 12 (50 %) – 2.482
Age (years)
 <70 38 (46.4 %) 37 (45.1 %) 7 (8.5 %) 0.6141
 ≥70 11 (42.3 %) 14 (53.9 %) 1 (3.8 %) 0.975
Smoking status
 Current smokers 35 (47.9 %) 31 (42.5 %) 7 (9.6 %) 0.3915
 Ex-smokers 11 (40.7 %) 15 (55.6 %) 1 (3.7 %) 4.109
 Non-smokers 1 (20 %) 4 (80 %) –
Histopathological diagnosis
 Adenocarcinoma 5 (41.7 %) 6 (50 %) 1 (8.3 %)
 Squamous cell carcinoma 34 (44.7 %) 37 (48.7 %) 5 (6.6 %) 0.9300
 Large cell carcinoma 5 (62.5 %) 2 (25 %) 1 (12.5 %) 1.885
 NOS NSCLC 5 (41.7 %) 6 (50 %) 1 (8.3 %)
Stage of disease
 IIIB 26 (48.15 %) 24 (44.45 %) 4 (7.4 %) 0.8252
 IV 23 (%) 27 (%) 4 (%) 0.360
Performance status
 PS = 0 14 (46.7 %) 14 (46.7 %) 2 (6.6 %) 0.9759
 PS ≥ 1 35 (44.9 %) 37 (47.4 %) 6 (7.7 %) 0.049
625Cancer Chemother Pharmacol (2015) 76:621–629 
1 3
the possibility of obtaining response to first-line CTH treat-
ment. Moreover, SNP (−2166T>C) of STMN1 gene did not 
affect significantly the type of response to first-line treatment.
Progression‑free survival
In the study population, median PFS (mPFS) was 
6.5 months. In patients who had no weight loss before 
CTH, mPFS was significantly longer compared with other 
patients (8 vs. 3 months; p = 0.0063, χ2 = 7.46; HR 0.47, 
95 % CI 0.27–0.81). In patients without anemia before 
CTH, mPFS were significantly longer compared with 
those who had this type of hematological disorders (8 vs. 
4.5 months; p = 0.011, χ2 = 6.46; HR 0.54, 95 % CI 0.33–
0.87). Patients undergoing RCTH characterized by signifi-
cantly longer mPFS compared with those treated only CTH 
(9 vs. 4 months; p = 0.0247, χ2 = 5.04; HR 0.58, 95 % 
CI 0.36–0.93). Patients with no cases of cancer in the fam-
ily had a significantly longer mPFS compared WITH other 
patients (6 vs. 1.5 months; p = 0.0168, χ2 = 5.72; HR 0.28, 
95 % CI 0.10–0.79). In addition, carriers of the TT geno-
type (−2166T>C) of STMN1 gene demonstrated signifi-
cant shortening in mPFS compared with patients with other 
polymorphic variants of this gene (2.75 vs. 6.5 months; 
p = 0.0033, χ2 = 8.63; HR 5.91, 95 % CI 1.81–19.33; 
Fig. 2). In the case of other demographic and clinical fac-
tors, there were no statistically significant differences in the 
duration of PFS in the study group.
Cox multivariate logistic regression demonstrated that 
the factors that significantly shortened PFS in a group of 
patients treated with CTH based on platinum compounds 
and vinorelbine (overall fit of the model: p = 0.0021, 
χ2 = 47.28) were: poor PS (p = 0.0008; HR 5.24, 95 % 
CI 1.99–13.79) and diagnosis of non-squamous type of 
NSCLC (p = 0.0188; HR 3.28, 95 % CI 1.22–8.78).
Overall survival
In the study population, median OS (mOS) was 12 months. 
Patients in good PS had significantly longer mOS com-
pared with other patients (19 vs. 10 months; p < 0.0392, 
χ2 = 4.25; HR 0.58, 95 % CI 0.35–0.97). In patients who 
had no weight loss before CTH, mOS was significantly 
longer compared with other patients (14 vs. 9 months; 
p = 0.0016, χ2 = 9.91; HR 0.39, 95 % CI 0.21–0.70). In 
patients without anemia before CTH, mOS was significantly 
longer compared with those who had this type of hemato-
logical disorders (15 vs. 10 months; p = 0.0362, χ2 = 4.38; 
HR 0.59, 95 % CI 0.36–0.97). Patients with no cases of 
cancer in the family had a significantly longer mOS in com-
parison with other patients (13 vs. 8 months; p = 0.0134, 
χ2 = 6.11; HR 0.27, 95 % CI 0.09–0.76). In the case of 
other demographic and clinical factors, there were no sta-
tistically significant differences in the duration of OS in the 
study group. There was no significant association between 
mOS and the occurrence of particular STMN1 genotypes 
(Fig. 3).
Cox multivariate logistic regression demonstrated, that 
the factor, that significantly shortened OS in the study 
group (overall model fit: χ2 = 55.05, p = 0.0001) was only 
poor PS (p < 0.0001; HR 30.77, 95 % CI 7.93–119.36).
All results of response to treatment, PFS, and OS are 
presented in Table 3.
Discussion
Selecting the most appropriate cytostatics combination is 
based primarily on the patients’ PS, adverse events, con-
venience of use, experiences, and personal preferences of 
physician. However, each of the available CTH regimens, 
Fig. 2  Probability of progression-free survival change depending on 
STMN1 genotype
Fig. 3  Probability of overall survival change depending on STMN1 
genotype
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regardless of the treatment line, is characterized by signifi-
cant differences in efficiency, i.e., in response rates, dura-
tion of PFS, and OS observed in individual patients. It is 
obvious that the resistance to systemic treatment does not 
apply equally all the patients, and is likely due to molecular 
differences.
Changes in the structure, expression, or function of 
various proteins may depend on the occurrence of SNPs in 
coding or noncoding sequences (mainly promoter) of dif-
ferent genes [15]. Molecular changes with potentially high-
est impact on the effectiveness of CTH are mainly related 
to the metabolism and mechanism of action of the chemo-
therapeutic agent. In contrast to the expression determined 
in tumor tissue, SNPs analysis can be carried out in materi-
als that are easy to obtain (e.g., DNA from peripheral blood 
leukocytes). Therefore, many studies (unfortunately mostly 
retrospective) examined the effects of the different poly-
morphic variants of various genes on the effectiveness of 
different treatment regimens [16–18].
In our recently published study, we have shown that 
SNP −2166C>T can be considered as a biomarker of the 
treatment efficiency in advanced NSCLC patients treated 
in second line of chemotherapy (monotherapy) with 
use of docetaxel or paclitaxel. These drugs are affecting 
mitotic spindle (similarly to vinorelbine which is currently 
used in first-line chemotherapy) [13]. In the available lit-
erature, there are no more publications containing data 
on the role of any STMN1 gene polymorphisms (includ-
ing −2166C>T) as risk, prognostic, or predictive factor 
in NSCLC patients. However, on the basis on the relation-
ship of changes in STMN1 gene expression and efficacy 
of therapies based on the taxane or vinca alkaloids in cell 
cultures and in cancer patients, it can be concluded about 
the potential importance of such genetic change. Despite 
the fact that the actual functional relevance of STMN1 
polymorphisms on the level of gene expression and pro-
tein function has not yet been established, SNPs in regu-
latory regions frequently affect gene expression. SNPs in 
the STMN1 gene alter the recognition motif and thus the 
potential binding of a transcription factor. Studied SNP is 
localized next to a consensus sequence of a glucocorticoid 
responsive element (steroidal hormones have been shown 
to modulate STMN1 expression and protein function) 
[14]. In studies of Alli et al. and Balachandran et al. [11, 
12] carried on breast and ovarian cancer cell lines, it was 
demonstrated that the increased expression of STMN1 had 
reduced microtubule polymerization (which significantly 
reduced binding of paclitaxel). Some studies also suggest 
that high expression of STMN1 may be associated with 
resistance not only to the taxanes but also to vinca alkaloids 
[19, 20]. Increased expression of this protein seems to have 
no influence on the effect of drugs, in which mechanism 
of action is not related with formation of microtubules. In 
a study of 54 female patients with advanced breast cancer 
who have received docetaxel as neoadjuvant CTH, Meng 
et al. [21] showed that low level of STMN1 expression is a 
good predictor indicating a high probability of response to 
applied therapy.
Moreover, to date only two studies assessed the asso-
ciation between the mRNA expression of STMN1 gene 
and disease progression or OS duration in patients treated 
with CTH. Among these publications, only one study con-
cerned the NSCLC patients (612 patients treated with CTH 
based on a combination of platinum with gemcitabine or 
vinorelbine, tissue material was available only from 75 
patients). In the subgroup of patients treated with the com-
bination of platinum compounds and vinorelbine, statisti-
cally significant effect of STMN1 gene expression (expres-
sion level ≤ 5 vs. > 5) on PFS duration (6.4 vs. 2.1 months, 
p = 0.05) has been shown. However, a significant relation-
ship between STMN1 gene expression and OS has not been 
reached. In quoted publication, the threshold cycle (CT) 
was the fractional cycle number at which the fluorescence 
generated by cleavage of the probe exceeded a fixed level 
above baseline. The relative amount of tissue target mRNA 
standardized against the amount of β-actin mRNA was 
expressed as −�CT =
[
CT(target gene - 1) − CT(β−actin)
]
. 
The ratio of the number of target mRNA copies to the 
number of b-actin mRNA copies was then calculated as 
2−CT × K, where K is a constant [20]. In the next study, 
Jila˘veanu et al. evaluated the relationship between expres-
sions of different proteins (including STMN1) with dura-
tion of PFS. Biomarker rating was carried out in 263 mela-
noma patients treated with the combination of carboplatin, 
paclitaxel, and sorafenib. However, no significant associa-
tion between STMN1 expression and duration of PFS and 
OS was observed [22].
In this study, we have shown for the first time that TT 
genotype of STMN1 gene (−2166T>C) may be associated 
with shortening of PFS in patients with locally advanced 
or metastatic NSCLC who received first-line chemother-
apy based on a combination of platinum compounds and 
vinorelbine. Limitation of our study was heterogeneous 
population (part of patients were subjected to chemoradio-
therapy and/or subsequent lines of CTH).
Conclusion
Rare TT genotype of STMN1 gene may be an unfavorable 
predictive factor of chemotherapy based on platinum com-
pounds and vinorelbine, in patients with NSCLC.
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